Blog

Chiesi dumps uniQure’s hemophilia B gene therapy – FierceBiotech


FierceBiotech

Chiesi dumps uniQure's hemophilia B gene therapy
FierceBiotech
Chiesi has cut its ties to uniQure's hemophilia B gene therapy. The split gives uniQure full rights to AMT-060 but leaves it without a partner to cofund R&D as it closes in on the start of a pivotal trial. Italian drugmaker Chiesi picked up the rights

2017-08-01 NEWS
About Michael Zand

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.